Showing 2231-2240 of 5771 results for "".
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Johnson & Johnson Vision Announces New Data, Products, and Physician Resources at AAO 2019https://modernod.com/news/johnson-johnson-vision-announces-new-data-products-and-physician-resources-at-aao-2019/2476994/Johnson & Johnson Vision is announcing a series of breakthrough data, technology, and products at the upcoming 2019 American Academy of Ophthalmology (AAO) annual meeting in San Francisco. The company will be announcing the FDA approval of the iDESIGN Refractive Studio Wavefront-guided PRK in
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- TECLens Announces Completion of Enrollment of a Pilot Clinical Study for the Treatment of Keratoconushttps://modernod.com/news/teclens-announces-completion-of-enrollment-of-a-pilot-clinical-study-for-the-treatment-of-keratoconus/2476980/TECLens announced the completion of enrollment of its pilot clinical study for the treatment of Keratoconus using the TECLens’ CXLens ‘on-eye’ cross-linking system for corneal remodeling. Clinical trial results are anticipated in early 2020. TECLens’ CXLens will pro
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- ProQR Announces Positive Topline Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patientshttps://modernod.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/ProQR Therapeutics announced positive topline results from the PQ-110-001 study, a phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported toda
- Avedro Announces Schedule of Events at AAOhttps://modernod.com/news/avedro-announces-schedule-of-events-at-aao/2476970/Avedro announced its schedule of scientific and educational programs focused on corneal cross-linking and keratoconus during the American Academy of Ophthalmology annual meeting in San Francisco. Avedro’s presentations and educational events underscore the clinical community’s
- Eyeris Announces Industry-First, Environmentally-Conscious Packaginghttps://modernod.com/news/eyeris-announces-industry-first-environmentally-conscious-packaging/2476959/Nashville-based start-up Eyeris recently announced its daily disposable contact lens that will be launching in January of 2020. Along with the lens, Eyeris created industry-first trial lens packa
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary